VCP disease is a rare inherited condition caused by mutations in the gene that produces valosin-containing protein, a cellular workhorse involved in protein cleanup and energy production. The disease is also called multisystem proteinopathy (MSP) because it can strike multiple organ systems, most commonly muscle, bone, and the brain. Because the same gene mutation can show up as muscle weakness in one person, abnormal bone growth in another, and dementia in a third, even within the same family, VCP disease is often misdiagnosed or diagnosed late. Understanding the condition requires looking at what the VCP protein actually does, what happens when it malfunctions, and how the resulting damage manifests across different tissues.
What the VCP Protein Does in Healthy Cells
Valosin-containing protein (also called p97) is one of the most abundant proteins in human cells, and it has an unusually long list of jobs. Its core role is quality control: it identifies damaged or misfolded proteins, extracts them from cellular structures, and routes them for disposal through the cell’s two main waste-processing systems. One system, the proteasome, chops defective proteins into small pieces. The other, autophagy, bundles larger waste into compartments that digest it. VCP helps decide which pathway a given piece of cellular trash follows.
Beyond protein cleanup, VCP plays a role in maintaining healthy mitochondria (the structures that generate energy for the cell), repairing damaged DNA, and managing the cell’s response to stress. A review of VCP’s molecular functions lists its involvement in processes ranging from DNA damage repair to cell division to the targeted destruction of faulty mitochondria.
How VCP Mutations Cause Disease
VCP disease follows an autosomal dominant inheritance pattern, meaning a person needs only one copy of the mutated gene (from one parent) to develop the condition. The mutations are typically missense variants, meaning a single building block in the gene’s code is swapped for a different one, producing a slightly altered protein. More than 50 different disease-causing VCP variants have been identified, and the most frequently reported one, R155H, accounts for a large share of known cases.
When the VCP protein is defective, the cell’s waste-disposal systems start to fail. Damaged proteins that should be broken down instead accumulate inside cells. One protein that piles up is TDP-43, which normally lives in the cell nucleus and helps regulate gene activity. In VCP disease, TDP-43 mislocalizes and forms clumps, or aggregates, in the cytoplasm outside the nucleus. Research using cells carrying two independent VCP mutations (A232E and R155H) has shown that, under stress, these mutant cells accumulate significantly more insoluble TDP-43 compared to cells with normal VCP. TDP-43 aggregates are a hallmark of several neurodegenerative diseases, and their presence in VCP disease connects it to a broader family of conditions including ALS and frontotemporal dementia.
The damage is not limited to protein buildup. Studies using patient-derived cells have found that VCP mutations cause profound problems in mitochondria. Specifically, the mutations lead to mitochondrial uncoupling, a state where the mitochondria consume oxygen but fail to produce a normal amount of energy in the form of ATP. One study showed that this uncoupling results from a slowdown in the transport of ADP and ATP across the mitochondrial membrane, essentially a bottleneck in the cell’s energy supply chain. Cells with these mutations produce less ATP overall, leaving them more vulnerable when energy demands spike, such as during physical exertion or cellular stress. A separate study confirmed decreased spare respiratory capacity and increased signs of glycolysis (an alternative, less efficient energy pathway) in VCP patient cells, reinforcing the picture of cells scrambling to compensate for an energy deficit.
The Three Classic Features
VCP disease was originally described as a triad of three conditions occurring together, which is why its older name, IBMPFD, is essentially an acronym for its three main features: inclusion body myopathy, Paget’s disease of bone, and frontotemporal dementia. Not everyone with VCP disease develops all three, and the age at which each feature appears varies widely.
Inclusion Body Myopathy
Muscle weakness is the most common feature, affecting roughly 90% of people with VCP mutations. It typically begins in adulthood, often between the ages of 30 and 60, and tends to affect the muscles around the hips and shoulders first. Over time, weakness can spread to the hands and feet as well. Case reports describe patients with wasting and weakness in both the proximal muscles (closer to the trunk) and distal muscles (further from the trunk). The weakness is progressive, and many people eventually need assistive devices like canes or wheelchairs. Under the microscope, muscle biopsies from these patients often show rimmed vacuoles, which are small holes bordered by debris that reflect the cell’s failure to clear damaged proteins.
Paget’s Disease of Bone
About half of people with VCP mutations develop Paget’s disease of bone, a condition in which the normal cycle of bone breakdown and rebuilding goes haywire. Bone is constantly being remodeled, with old bone dissolved and new bone laid down in its place. In Paget’s disease, this process speeds up and becomes disorganized, producing bone that is larger, weaker, and prone to pain and fractures. It tends to affect the spine, pelvis, and skull. Elevated levels of a blood marker called alkaline phosphatase can be an early clue, sometimes showing up before symptoms appear.
Frontotemporal Dementia
Roughly a third of VCP mutation carriers develop frontotemporal dementia (FTD), a form of cognitive decline that primarily affects personality, behavior, and language rather than memory (which distinguishes it from Alzheimer’s disease in its early stages). People with FTD may become socially inappropriate, apathetic, or impulsive, or they may lose the ability to find words and construct sentences. In VCP disease, FTD tends to appear later than the myopathy or bone disease, often in the fifth or sixth decade of life.
Beyond the Classic Triad
As more families with VCP mutations have been studied, it has become clear that the disease’s reach extends beyond muscle, bone, and the frontal lobes. A genotype-phenotype study across 36 families found that about 9% of patients with VCP mutations had an ALS-like picture of upper and lower motor neuron degeneration, roughly 4% had been diagnosed with Parkinson’s disease, and about 2% had received an Alzheimer’s disease diagnosis. These numbers are small, but they show that VCP mutations can produce clinical pictures that overlap with several other well-known neurological conditions, making diagnosis harder.
Other reported features include cardiomyopathy (disease of the heart muscle), cataracts, and hearing loss. The list continues to grow as genetic testing becomes more widespread and clinicians learn to connect disparate symptoms back to a single gene. Parkinsonism, characterized by tremor, stiffness, and slow movement, is now formally included in the broader definition of VCP-related multisystem proteinopathy.
Why Symptoms Vary So Much
One of the most confusing aspects of VCP disease is its variability. Two siblings carrying the identical mutation can have strikingly different symptoms and disease trajectories. One might develop muscle weakness in their thirties while the other remains asymptomatic into their fifties and then presents with dementia. A study examining genotype-phenotype correlations across VCP families found marked intra-familial and inter-familial variation, with meaningful genotype-phenotype correlations difficult to establish due to small numbers. This variability suggests that other genetic factors, environmental influences, or random biological events modify how a VCP mutation expresses itself in any given person.
The R155H mutation, the most common variant, has been associated with the full range of disease features, but even among R155H carriers, the combination and severity of symptoms differ. This unpredictability creates a practical challenge: presymptomatic carriers (family members who have tested positive for the mutation but have no symptoms yet) need ongoing monitoring, because there is no way to predict exactly when or how the disease will surface. Expert panels have recommended that these individuals be screened at regular intervals for early signs of myopathy, bone disease, and cognitive changes.
How VCP Disease Is Diagnosed
Because VCP disease can mimic several more common conditions (limb-girdle muscular dystrophy, sporadic Paget’s disease, Alzheimer’s, ALS), it is often not the first diagnosis clinicians consider. Genetic testing is the only definitive way to confirm it. For someone with a known family history, targeted testing for the specific familial variant is straightforward. For someone presenting without a known family connection, multi-gene panel sequencing that includes VCP among other neuromuscular or proteinopathy-related genes is the typical approach.
Muscle biopsy plays an important supporting role. Rimmed vacuoles, present in roughly 40% of VCP myopathy cases, are considered a hallmark finding when they appear. Electrodiagnostic studies (nerve conduction tests and electromyography) and MRI of affected muscles can help rule out other conditions that look similar. Blood tests for creatine kinase (a marker of muscle damage) are often only mildly elevated, which can actually be a useful clue, since some other myopathies produce much higher levels.
Imaging studies such as bone scans or X-rays may reveal Paget’s disease in bones that are not yet causing pain. Neuropsychological testing can detect early cognitive changes before they are obvious in daily life. The challenge is assembling these pieces into a coherent picture, especially when only one feature of the disease is present at the time of evaluation.
Managing VCP Disease Today
There is no cure for VCP disease and no treatment that slows or reverses the underlying protein and mitochondrial dysfunction. Management focuses on addressing each affected system individually and preserving function for as long as possible.
Myopathy
Physical and occupational therapy are central to managing the muscle component. A standard-of-care document developed for VCP-associated multisystem proteinopathy recommends regular aerobic exercise at low to moderate intensity, with monitoring, to preserve strength, range of motion, endurance, and balance. The same guidelines caution that inactivity leads to further weakness and functional decline, so the goal is to maintain activity without overloading muscles that are already compromised. Assistive devices, home modifications, and eventually respiratory support may become necessary as the disease progresses, because the muscles involved in breathing can also weaken over time.
Paget’s Disease of Bone
The bone component is the most directly treatable feature of VCP disease. Bisphosphonates, a class of drugs that slow down the cells responsible for bone breakdown, are the standard treatment for Paget’s disease regardless of its cause. Among the bisphosphonates, zoledronate is a particularly useful option because a single intravenous dose can suppress abnormal bone turnover for months or even years. Treatment can reduce pain, lower the risk of fractures, and normalize alkaline phosphatase levels.
Cognitive and Behavioral Symptoms
Frontotemporal dementia has no disease-modifying treatment. Management is supportive and involves behavioral strategies, speech and language therapy when communication is affected, and sometimes medications to manage specific symptoms like agitation or compulsive behavior. Caregiver support becomes increasingly important as the dementia progresses. Early neuropsychological evaluation can help families plan ahead.
Other Features
ALS-like motor neuron involvement may require its own supportive care, including respiratory support and interventions for swallowing difficulties. Parkinsonism may respond to levodopa in some cases, though the evidence in VCP-specific parkinsonism is limited. Cardiac involvement, when present, warrants monitoring by a cardiologist.
The Role of Coordinated Care
Because VCP disease can affect so many organ systems, management works best when coordinated across specialties. A neurologist may lead the overall care, but the team can include rheumatologists or endocrinologists for Paget’s disease, pulmonologists for respiratory decline, cardiologists for heart involvement, speech-language pathologists for swallowing and communication problems, and genetic counselors for family planning and testing of at-risk relatives. This kind of multidisciplinary approach is standard for other complex genetic conditions, but for something as rare as VCP disease, finding clinicians with direct experience can be difficult. Many families end up at academic medical centers that specialize in neuromuscular or rare genetic diseases.
Research and Emerging Therapies
The absence of a disease-modifying therapy has driven active research on multiple fronts. Because VCP mutations disrupt protein clearance, autophagy, and mitochondrial function, each of these pathways represents a potential therapeutic target. A review of therapeutic developments in VCP disease highlights work on compounds that aim to restore normal autophagy, reduce TDP-43 aggregation, and correct mitochondrial energy deficits. Some of these approaches are being investigated in cell and animal models but have not yet reached human clinical trials for VCP disease specifically.
One line of research has explored VCP activators, compounds designed to boost the activity of the mutant protein and restore its function. Preclinical work has shown that a novel VCP activator can enhance the clearance of TDP-43 aggregates in mutant cells and correct some of the nuclear protein-handling defects caused by VCP mutations. Whether these laboratory results translate into human benefit remains to be seen, but the concept of pharmacologically rescuing a partially functional protein is promising.
Gene therapy is another area of interest. Approaches that could deliver a functional copy of the VCP gene, silence the mutant copy, or edit the mutation itself are all theoretically applicable, and similar strategies are being tested for other genetic neuromuscular conditions. The challenge with VCP disease is that the protein is active in nearly every cell type, so any gene therapy would need to reach multiple tissues to address the full spectrum of symptoms.
Genetic Counseling and Family Planning
Because VCP disease is autosomal dominant, every child of an affected parent has a 50% chance of inheriting the mutation. Genetic counseling is a key part of care for affected families. Predictive testing can identify carriers before symptoms appear, but this raises difficult decisions. Knowing you carry the mutation means living with the awareness that disease may develop, without knowing when or which features will appear. Some people choose not to be tested. Others want the information so they can plan monitoring, career decisions, and family planning.
For carriers who wish to have children without passing on the mutation, preimplantation genetic testing during in vitro fertilization (IVF) can screen embryos for the familial variant before implantation. Prenatal testing through amniocentesis or chorionic villus sampling is also available but is used less frequently for adult-onset conditions.
Presymptomatic carriers who do choose to know their status benefit from regular screening. Expert recommendations include periodic assessments of muscle strength, blood tests for alkaline phosphatase, and cognitive screening, so that emerging features can be caught early and managed proactively. The intervals and specific tests vary among clinical centers, since no universally standardized surveillance protocol exists yet for presymptomatic VCP carriers.
How VCP Disease Relates to Other Proteinopathies
VCP disease sits within a larger family of conditions linked to problems with protein handling in cells. TDP-43 aggregation, the same pathological finding seen in VCP disease, also occurs in the majority of ALS cases and in a significant subset of frontotemporal dementia cases that have nothing to do with VCP. Similarly, mitochondrial dysfunction is a shared feature across many neurodegenerative diseases. This overlap means that treatments developed for more common conditions like ALS or Parkinson’s disease could potentially benefit VCP patients as well, and vice versa. Research into VCP function has already contributed insights into how protein clearance pathways go wrong more broadly, making it relevant to neuroscience well beyond the small population of VCP mutation carriers.
The connection to TDP-43 pathology is particularly notable. Studies have shown that in VCP disease, TDP-43 accumulates within the ubiquitin-positive inclusions found in affected neurons and muscle fibers, while the mutant VCP protein itself is not found inside these inclusions. This observation supports the idea that VCP mutations cause a loss of normal VCP function at the cellular level, resulting in a failure to degrade TDP-43 properly, rather than VCP itself forming toxic clumps. Understanding this distinction matters because it points toward therapeutic strategies focused on restoring clearance pathways rather than blocking a toxic gain of function.